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ABSTRACT 
In recent years, the outcome of mantle cell lymphoma has improved, especially in younger 
patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem cell 
transplantation. Nevertheless, a proportion of mantle cell lymphoma patients still experience early 
failure. To identify biomarkers anticipating failure of intensive chemotherapy in mantle cell lymphoma, 
we performed target resequencing and DNA profiling of purified tumor samples collected from patients 
enrolled in the prospective FIL-MCL0208 phase III trial (high-dose chemoimmunotherapy followed by 
autologous transplantation and randomized lenalidomide maintenance). Mutations of KMT2D and 
disruption of TP53 by deletion or mutation associated with an increased risk of progression and death, 
both in univariate and multivariate analysis. By adding KMT2D mutations and TP53 disruption to the 
MIPI-c backbone, we derived a new prognostic index, the “MIPI-genetic”. The “MIPI-g” improved the 
model discrimination ability compared to the MIPI-c alone, defining three risk groups: i) low-risk 
patients (4-years progression free survival and overall survival of 72.0% and 94.5%); ii) intermediate-
risk patients (4-years progression free survival and overall survival of 42.2% and 65.8%) and iii) high-
risk patients (4-years progression free survival and overall survival of 11.5% and 44.9%). Our results: 
i) confirm that TP53 disruption identifies a high-risk population characterized by poor sensitivity to 
conventional or intensified chemotherapy; ii) provide the pivotal evidence that patients harboring 
KMT2D mutations share the same poor outcome as patients harboring TP53 disruption; and iii) allow 
to develop a tool for the identification of high-risk mantle cell lymphoma patients for whom novel 
therapeutic strategies need to be investigated. (Trial registered at clinicaltrials.gov identifier: 
NCT02354313) 
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INTRODUCTION 
The introduction of high dose cytarabine-containing chemoimmunotherapeutic regimens and 
autologous transplantation (ASCT) have considerably improved the outcome of young fit mantle cell 
lymphoma (MCL) patients. Nonetheless, approximately 20 to 25% of MCL patients demonstrate 
inadequate efficacy of intensified chemoimmunotherapy as they are either primary refractory or relapse 
within two years from autologous stem cell transplantation.1-5  
Clinical and pathological scores, including the MCL international prognostic index (MIPI),6 the 
Ki-67 proliferative index,7 and their combination in the MIPI-c score, stratify MCL patients in groups 
at different risk of relapse.8 However, none of these tools has sufficient positive predictive value to 
trigger the development of tailored schedules specifically designed for high risk patients.9  
Several recurrent mutations have been described in MCL, affecting DNA repair genes and cell 
cycle regulators (TP53, ATM, CCND1), epigenetic regulation genes (KMT2D, WHSC1) and cell-
signaling pathways genes (NOTCH1-2, BIRC3, TRAF2).10-12 The proof of principle that MCL genetics 
can impact on disease outcome stems from studies that have focused on the TP53 tumor suppressor 
gene, including both mutations and 17p deletions.13-17 
We prospectively assessed the clinical impact of a panel of genomic alterations in a cohort of 
young MCL patients treated with high dose chemoimmunotherapy and ASCT from the Fondazione 
Italiana Linfomi (FIL) “MCL0208” phase III trial.18 The results document that KMT2D mutations 
associate with poor outcome in MCL and, along with TP53 mutations and 17p deletions, might be 
integrated in a new prognostic score to segregate a subgroup of patients who obtain minimal or no 
benefit from intensive chemoimmunotherapy. The prognostic score was validated in an independent 
series of cases. 
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METHODS 
 
Patients series 
The FIL-MCL0208 (NCT02354313) is a phase III, multicenter, open-label, randomized, 
controlled study, designed to determine the efficacy of lenalidomide as maintenance versus observation 
in young (18-65 years old), fit, advanced stage (Ann arbor II-IV) MCL patients after first line 
intensified and high-dose chemo-immunotherapy followed by ASCT. Cases of non-nodal MCL were 
excluded.19 The clinical trial, as well as the ancillary mutational study, were approved by the Ethical 
Committees of all the enrolling Centers. All patients provided written informed consent for the use of 
their biological samples for research purposes, in accordance with Institutional Review Boards 
requirements and the Helsinki's declaration. Clinical results of the fist interim analysis of the trial were 
already presented.18 Further information are supplied in the Supplementary appendix. 
 
Biological samples 
Tumor cells were sorted from the baseline BM samples by immunomagnetic beads (CD19 
MicroBeads,human-Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and stocked as dry pellets.  
Tumor DNA was extracted according to DNAzol protocol (Life Technologies). Germline DNA was 
obtained from PB mononuclear cells collected under treatment and proven to be tumor free by MRD 
analysis. Further information are supplied in the Supplementary appendix. 
 
Next generation sequencing 
A targeted resequencing panel (target region: 37’821 bp) (Table S1) including the coding exons 
and splice sites of 7 genes (ATM, TP53, CCND1, WHSC1, KMT2D, NOTCH1 exon 34, BIRC3) that are 
recurrently mutated in ≥ 5% of MCL tumors was specifically designed.10-12 We also included in the 
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panel TRAF2 20 and CXCR4.21 NGS libraries preparation was performed using TruSeq Custom 
Amplicon sequencing assay according to manufacturer’s protocol (Illumina, Inc., San Diego, CA). 
Multiplexed libraries (n=48 per run) were sequenced using 300-bp paired-end runs on an Illumina 
MiSeq sequencer, (median depth of coverage 2356x). A robust and previously validated bioinformatics 
pipeline was used for variant calling (Supplementary Appendix). Copy number variation analysis 
methods22,23 are supplied in the Supplementary Appendix.  
 
Minimal residual disease analysis  
For MRD purposes, MCL diagnostic BM and PB samples were investigated for IGH gene 
rearrangements and BCL1/IGH MTC by qualitative PCR.24-26 Both BM and PB samples were analyzed 
for MRD at specific time points during and after treatment. Further information are supplied in the 
Supplementary appendix.  
 
Statistical analysis 
The primary outcome of the clinical study was progression-free survival (PFS) and secondary 
outcomes included overall survival (OS).27 The adjusted effects of mutations and exposure variables 
(MIPI-c and blastoid variant) on PFS and OS were estimated by Cox regression. To compare clinical 
baseline features between patients enrolled in the molecular study and patients not included in the 
analysis, we used Mann-Whitney test for continuous variables and Pearson’s chi-squared test for 
categorical variables. Statistical analyses were performed using Stata 13.0 and R 3.4.1. Further 
information are supplied in the Supplementary appendix. 
 
Validation set 
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The Nordic Lymphoma Group “MCL2” and “MCL3”, phase 2, prospective trials17 were used 
for independent validation of our findings. In particular, the raw sequencing data of the study by 
Eskelund were reanalyzed according to our bioinformatics pipeline (detailed before), to get a uniform 
mutation calling.  
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RESULTS 
Patients characteristics  
Out of the 300 patients enrolled in the FIL-MCL0208 clinical trial, 186 (62%) were provided 
with CD19+ sorted tumor cells from the BM and evaluable for both mutations and copy number 
abnormalities. Moreover, four more patients were provided with the copy number abnormalities data 
only. Baseline features of cases included in the molecular study overlapped with those of cases not 
included in the molecular analysis because of lack of tumor material in the BM aspirates. As expected, 
tumor cells were obtained more frequently in cases with BM infiltration documented by morphological 
or flow-cytometry analysis (Table 1). Overall, this observation did not introduce a selection bias, since 
cases evaluable for genomic studies showed a similar outcome to that of cases not analyzed, both in 
terms of PFS and OS (Figure S1).  
 
Description of genomic alterations 
At least one somatic non-synonymous mutation affecting genes of the target region was 
observed in 69.8% of patients (130/186) (Figure 1, Figure S2; Table S2). Mutated genes were ATM 
(41.9%), followed by WHSC1 (15.6%), KMT2D (12.4%), CCND1 (11.8%), TP53 (8.1%), NOTCH1 
(7.5%), BIRC3 (5.9%) and TRAF2 (1.1%). KMT2D deletion occurred in 1.6% of patients (3/190) and 
TP53 deletion in 13.2% patients (25/190). TP53 was inactivated by mutations or deletions in 31/186 
(16.6%) cases, including 8/186 (4.3%) mutated/deleted cases, 16/186 (8.6%) deleted but not mutated 
cases, and 7/186 (3.7%) mutated but not deleted cases. KMT2D was inactivated by mutations or 
deletions in 25/186 (13.4%) cases, including 1/186 (<1%) mutated/deleted case, 2/186 (<1%) deleted 
but non mutated cases, and 22/186 (11.8%) mutated but not deleted cases.  
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KMT2D mutations and TP53 disruption associate with poor outcome in MCL 
By univariate analysis, mutations of KMT2D were associated with poor clinical outcome in 
terms of both PFS and OS. At 4 years, the PFS of KMT2D mutated patients was 33.2% vs 63.7% 
(p<0.001) in wild type cases (Figure 2 A). The OS of KMT2D mutated patients was 62.3% vs 86.8% 
(p=0.002) in wild type patients (Figure 2 B). Consistent with previous reports, both TP53 mutations 
and deletion associated with shorter PFS and OS at 4 years (Figure 2 C,D and Figure 3). In detail, the 
negative prognostic impact for TP53 disruption was equal for all the three inactivation modalities, 
which were then considered as a single group for further analyses (Figure S3). No further survival 
analysis was performed on KMT2D deletions, given the low frequency of this genetic lesion. All the 
other investigated mutations did not show strong association with PFS or OS (Figures S4-6 and Table 
S3). 
Patients harboring TP53 disruption were significantly enriched in known high-risk features of 
MCL. Indeed, 48.3% of the TP53 disrupted patients had Ki-67 ≥30%, 37.9% scored in the higher 
MIPI-c risk classes (i.e. “intermediate-high” and “high”), and 22.6% showed blastoid morphology. 
Conversely, 45.5% of cases harboring KMT2D mutations scored in the higher MIPI-c risk classes but 
did not associate with Ki-67 expression or blastoid morphology (Table S4). Moreover, KMT2D 
mutated patients showed slightly higher beta-2 microglobulin (B2M) median values, as well as higher 
prevalence of B symptoms and bulky disease (>5 cm) than wild type patients (all p<0.05). 
Interestingly, also TP53 disrupted patients showed slightly higher B2M median values (p<0.05) than 
wild type patients (Table S4) and were associated with a high rate of disease progression during 
treatment (9 out of 31 patients, 29%). Moreover, TP53 disrupted patients reached lower levels of MRD 
negativity after ASCT, if compared with wild type ones: 35% vs 58% in BM (p=0.06) and 58% vs 80% 
in PB (p=0.04), respectively. Similar trends were seen for KMT2D mutated patients (46% vs 55% in 
BM and 58% vs 79%), albeit not statistically significant (Table S5).  Analogous to the Nordic 
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Lymphoma Group MCL2 and MCL3 trials17, also in our study morphological BM involvement was 
significantly associated with the presence of mutations in any of the genes analysed (p < 0.05). 
However, both TP53 disruptions and KMT2D mutations were equally distributed in patients with and 
without BM involvement (p = 0.26 and p = 0.32, respectively). 
By multivariate analysis adjusted for the validated risk factors MIPI-c and blastoid variant, both 
KMT2D mutations and TP53 disruptions maintained an independent increased hazard of progression 
and death (Table 2 and S6).  Patients carrying at least one of these genetic lesions, namely KMTD2 
mutations, TP53 mutations or deletion (n=49/186, 26.3%), had a 4-year PFS of 32.0% vs 69.9% of 
wild type patients (p<0.0001) and a 4-year OS of 65.1% vs 90.3% (p<0.0001), respectively (Figure 4).  
 
Integration of a genetic score into the MIPI-c: the “MIPI-g” model 
In order to integrate the clinical impact of KMT2D mutations and TP53 disruptions into the 
MIPI-c prognostic index (complete data available for 172 patients), we assigned a score to each of the 
single variables, based on the multivariate Cox regression analysis. MIPI-c low, low-intermediate and 
intermediate-high risk classes scored 0 points, MIPI-c high-risk class scored 1 point, while KMT2D 
mutations as well as TP53 disruption scored 2 points (Table 3). Patients were then grouped into three 
risk classes, according to their total score, in the “MIPI-genetic” index (“MIPI-g”), namely: i) 0 points, 
low risk group (LR 121 patients, 70.3%); ii) 1-2 points, intermediate risk group (IR 38 patients, 
22.1%); iii) ≥3 points, high risk group (HR 13 patients, 7.6%). PFS and OS at 4-years for low-, 
intermediate-, and high-risk groups were 72.0%, 42.2%, 11.5% (p<0.0001) and 94.5%, 65.8%, 44.9% 
(p<0.0001), respectively (Figure 5). The MIPI-g index improved the model discrimination ability, with 
a C-statistics of 0.675 for PFS (bootstrapping corrected 0.654) and 0.776 for OS (bootstrapping 
corrected 0.747), as compared to MIPI-c alone (C-statistics 0.592 and 0.7, respectively). 
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Validation set 
Most KMT2D variants considered in the Nordic study have been removed by our mutational 
calling, since these were missense variants not reported in COSMIC. At the end of the re-analysis, from 
the original 28 mutations, 21 were excluded. Two previously unrecognized frameshift mutations have 
been identified by our bioinformatics pipeline, overall accounting for a total of 9 KMT2D mutations (all 
disrupting, as expected for KMT2D) in the Nordic validation series. In the Nordic validation series, 
KMT2D mutated patients showed a similar increased risk for OS, with a median OS 12.7 years (95% 
C.I. not evaluable) for wild type vs. 8.4 (95% C.I 0-17.6) for mutated cases. The Nordic validation 
series also replicated the MIPI-g score. The re-analysis of TP53 mutations confirmed the original data 
of Eskelund et al., with median OS of 12.7 (95% C.I. not evaluable) for wild type cases and 2.0 years 
(95% C.I, 1.2-2-8) for mutated cases. Consistently, also the MIPI-g validation on the Nordic series 
showed similar results: 4-year OS for LR (N=103), IR (N=36) and HR (N=13) MIPI-g groups were 
91.3%, 72.2%, 15.4%.  
 
DISCUSSION 
To identify new molecular predictors in MCL, we performed targeted resequencing and DNA 
profiling of purified tumor samples collected from younger patients enrolled in the ASCT-based 
prospective FIL-MCL0208 phase III trial (NCT02354313). Our study documents that: i) KMT2D 
mutations are a novel, independent, adverse genetic biomarker in MCL, impacting both on PFS and OS 
(Figure 2 A,B); ii) TP53 aberrations (both mutations and deletion) prospectively confirm their adverse 
prognostic value in younger MCL patients receiving high-dose chemo-immunotherapy followed by 
ASCT, both in terms of PFS and OS (Figures 2 C,D and Figure 3); iii) identification of either KMT2D 
mutations or TP53 disruption (or both) defines a high-risk group of young MCL patients whose 
outcome is still not satisfactory despite intensive immunochemotherapy and ASCT (Figure 4); iv) these 
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biomarkers may be incorporated into a “genetic” MIPI-c (“MIPI-g”) model, accounting for three risk 
classes (Figure 5), that improve the C-statistics discrimination ability on survival, if compared to MIPI-
c alone. 
The adverse prognostic value of TP53 mutations in MCL has been already observed in some 
retrospective series,13-17 and has been recently confirmed in a combined series from two, ASCT-based, 
phase II trials of the Nordic Lymphoma Group.17 TP53 deletions impacted on both PFS and OS in the 
randomized, phase III European MCL Network “Younger” trial,16 while these data were not confirmed 
by multivariate analysis in the Nordic study, due to the high association with TP53 mutations.17 Our 
prospective study performed in a similar patient population of young MCL patients demonstrates that 
the presence of either TP53 mutations or deletions or both associates with poor prognosis. Importantly, 
although TP53 aberrations associated with elevated Ki-67, higher MIPI-c classes and blastoid 
morphology, their impact on survival was independent of these known risk factors. Moreover, TP53 
disrupted patients show higher levels of MRD positivity after ASCT, as described in Table S5. Finally, 
some previous studies reported also a negative impact of NOTCH1 mutations in univariate analysis,10,17 
however in our cohort these mutations were not an independent predictor of survival, as most of them 
co-occurred with TP53 mutations.   
In the FIL-MCL0208 trial, KMT2D mutations emerged as a novel biomarker heralding chemo-
immunotherapy failure, with a predictive value similar to that of TP53 aberrations. KMT2D (Lysine 
Methyltransferase 2D), also known as MLL2, acts as a tumor suppressor gene mutated in several B-cell 
lymphoma types, including 10-15% of MCL.28-31 Even though KMT2D mutated patients of the FIL-
MCL0208 trial scored in the higher MIPI-c risk classes, they did not show either elevated Ki-67 or 
blastoid morphology, suggesting that KMT2D mutations capture high-risk patients not otherwise 
identifiable through conventional pathologic parameters.  
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To the best of our knowledge, the adverse impact on cancer survival of KMT2D mutations has 
not been documented to date. No impact on survival was found for KMT2D mutations in the Nordic 
study.17 The lack of impact on survival of KMT2D mutations in the Nordic MCL series might be 
related to two main reasons. First, in the Nordic series, most KMT2D mutations were missense 
sequence variants (15/28) not reported as somatic variants in the COSMIC database, and therefore not 
fulfilling the criteria of “true” mutations. Conversely, in our series 74% of KMT2D mutations were 
protein truncating events, as expected28-31. Second, since Eskelund et al. performed mutational analysis 
in unsorted bone marrow samples, the low or absent tumor content of many cases might lead to 
underestimate KMT2D “true” mutations. By applying our bioinformatics pipeline to the raw 
sequencing data of the MCL2 and MCL3 Nordic Lymphoma Group trials, we validated the poor 
prognostic role of KMT2D mutations in an independent prospective cohort. 
The independent adverse prognostic value of TP53 and KMT2D aberrations prompted us to 
integrate the molecular results into the MIPI-c,8 aiming at further improving its ability to discriminate 
high-risk patients. The “MIPI-genetic” (“MIPI-g”) was able to divide patients into three risk classes, on 
the basis of a simple score given to each variable (namely: MIPI-c class, TP53 disruption and KMT2D 
mutations). Patients in the high “MIPI-g” risk groups may deserve new treatments, and a simple tool 
like the MIPI-g might be proposed in a future, “tailored” trial to select high-risk MCL patients for 
targeted experimental strategies. 
Our study suffers from some limitations. The analyses were performed only on CD19+ sorted 
BM cells and no tissue control is available at the moment; this issue might represent a limit for the 
extrapolation of the results to lymph-node samples, as across-compartment heterogeneity of the 
mutational landscape is described in MCL.10 However, the CD19+ selection approach we used, 
increasing the purity of tumor cells and, consequently, the sensitivity of our mutational approach, 
ensured that all the analyzed samples are representative of MCL. Therefore, we set a VAF threshold of 
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10% to call a mutation, accordingly to ERIC guidelines for the mutational analysis of the TP53 gene in 
chronic lymphocytic leukemia.32 Although we acknowledge that the present validation relies on a 
limited number of KMT2D mutated patients, we note that the Nordic trials are currently the only 
prospective studies with prompt available mutational data, adequate clinical follow-up and similar 
characteristics (i.e. patients age and treatment schedule), to validate our original findings from the 
“FIL-MCL0208” trial. 
The impact of lenalidomide maintenance in the FIL-MCL0208 trial on the described genetic 
aberrations has not been addressed, as complete data on randomization are not available yet. However, 
it should be noted that due to the high number of progressive diseases in the aberrant TP53/KMT2D 
group, 27 patients have been finally randomized but only 9 actually started lenalidomide maintenance. 
Therefore, it is unlikely that lenalidomide might play a clear role in driving the outcome of these 
patients and the trial will probably not be able to fully address this issue even with longer follow-up. 
In conclusion, our results show that KMT2D mutated and/or TP53 disrupted younger MCL 
patients are a high-risk population, characterized by poor sensitivity even to intensified chemo-
immunotherapy. Given the negative prognostic impact of these genetic lesions, they might be used to 
select high-risk patients for novel therapeutic approaches that can circumvent these detrimental genetic 
lesions. As in other lymphoid disorders, novel non-chemotherapeutic strategies specifically designed 
for high-risk patients need to be investigated in MCL. Besides the approved drugs lenalidomide and 
ibrutinib, new molecules such as the Bcl-2 inhibitor venetoclax might be very promising for these 
chemorefractory patients, especially for TP53 disrupted cases.33,34 Moreover, as the majority of 
KMT2D mutated and/or TP53 disrupted patients of our series actually achieve a response, though short-
lasting after ASCT, an alternative consolidation with allogeneic transplantation deserves investigation.  
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Table 1. Clinical and biological baseline characteristics of the patients included and not included 
in the molecular analysis 
 
Characteristics 
Patients analysed for 
mutations and/or CNV 
(N=190) 
Patients not analysed 
for mutations and CNV 
(N=110) 
P-value 
Median age 
57 58 0.987 
Gender 
    
0.090 
Female 
47 (24.7%) 18 (16.4%) 
Male 
143 (75.3%) 92 (83.6%) 
Ki-67 
    
0.210 
<30% 
126 (71.6%) 61 (64.2%) 
≥30% 
50 (28.4%) 34 (35.8%) 
Median WBC 
74500/ul 75000/ul 0.567 
ECOG 
    
0.722 
0 
144 (75.8%) 87 (79.2%) 
1 
40 (21.1%) 19 (17.3%) 
2 
6 (3.2%) 4 (3.6%) 
Median LDH 
275.5 UI/L 298 0.848 
Risk class MIPI 
    
0.562 
Low 
114 (60.0%) 66 (60.0%) 
Intermediate 
49 (25.8%) 24 (21.8%) 
High 
27 (14.2%) 20 (18.2%) 
Risk class MIPI-c 
    
0.685 
Low 
88 (50.0%) 45 (47.4%) 
Low-Intermediate 
49 (27.8%) 30 (31.6%) 
Intermediate/High 
25 (14.2%) 10 (10.5%) 
High 
14 (8.0%) 10 (10.5%) 
BM Invasion 
    
<0.001 
No 
26 (13.9%) 37 (33.9%) 
Yes 
161 (86.1%) 72 (66.1%) 
Median BM invasion by 
flow (%) 
10% 0.8% <0.0001 
Histology 
    
0.842 
MCL Classic 
174 (91.6%) 100 (90.9%) 
MCL blastoid variant 
16 (8.4%) 10 (9.1%) 
Bulky mass 
    
0.315 
No 
124 (65.3%) 78 (70.9%) 
Yes 
66 (34.7%) 32 (29.1%) 
CNV, Copy Numer Variation Analysis; WBC, White Blood Cells; ECOG, Eastern Cooperative Oncology Group; LDH, 
Lactate dehydrogenase; MIPI, MCL International Prognostic Index; MIPI-c, Combined MIPI; BM, Bone Marrow 
Table 2. Uniavariate and multivariate Cox-regression analysis in terms of PFS an OS 
 
  Progression free survival   Overall survival 
  
Univariate  
  
Multivariate                    
(MIPI-c and blastoid variant 
adjusted) 
  
Univariate 
  
Multivariate                    
(MIPI-c and blastoid variant 
adjusted) 
Genes HR 95% CI  P-value   HR 95% CI  P-value   HR 95% CI  P-value   HR 95% CI  P-value 
ATM mut 1.29 0.84-1.97 0.245   1.19 0.77-1.83 0.432   1.52 0.62-2.51 0.527   1.05 0.52-2.12 0.887 
WHSC1 mut 1.53 0.90-2.60 0.119   1.51 0.87-2.61 0.140   0.85 0.30-2.41 0.755   0.741 0.25-2.15 0.581 
CCND1 mut 0.83 0.41-1.66 0.595   0.94 0.46-1.92 0.860   0.75 0.23-2.48 0.643   1.01 0.29-3.53 0.980 
KMT2D mut 2.59 1.50-4.48 0.001   2.74 1.55-4.84 0.001   3.20 1.48-6.92 0.003   2.48 1.12-5.46 0.024 
TP53 mut 2.84 1.57-5.13 0.001   2.55 1.36-4.78 0.003   5.28 2.44-11.45 <0.0001   2.78 1.09-7.06 0.032 
NOTCH1 mut 1.86 0.93-3.72 0.078   1.57 0.76-3.24 0.226   1.34 0.41-4.40 0.629   0.61 0.17-2.12 0.609 
BIRC3 mut 0.88 0.32-2.41 0.807   0.70 0.25-1.96 0.500   1.84 0.56-6.08 0.315   1.15 0.33-3.98 0.822 
TP53 del 3.51 2.09-5.88 <0.0001   3.13 1.73-5.68 <0.001   4.46 2.14-9.29 <0.0001   2.65 1.06-6.59 0.036 
TP53 dis 3.39 2.10-5.45 <0.0001   3.17 1.87-5.38 <0.0001   4.26 2.09-8.67 <0.0001   2.65 1.10-6.37 0.030 
Del, deleted; dis, disrupted; PFS, Progression Free Survival; OS, overall survival; HR, Hazard Ratio; CI, Confidence Interval. 
 
 
Table 3. The MIPI-g score 
 
Variables  
Beta-
coefficients 
Points 
KMT2D mutations 1,035,607 2 
TP53 disruption 1,113,875 2 
MIPI-c     
Low - 0 
Low-Intermediate  - 0 
Intermediate-High - 0 
High  0.6847757 1 
MIPI-c, Combined Mantle Cell International Prognostic Index 
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FIGURE LEGENDS 
Figure 1. Overview on prevalence and molecular spectrum of non-synonymous somatic 
mutations discovered in patients’ tumor DNA.  Heatmap representing the mutational profiles of 186 
MCL cases, genotyped on tumor DNA (and four additional patients with copy number abnormalities 
data only). Each column represents one patient, each row represents one gene. The fraction of patients 
with mutations in each gene is plotted on the right. The number of aberrations in a given patient is 
plotted above the heatmap.  
 
Figure 2. Prognostic impact of KMT2D and TP53 mutations. Kaplan-Meier estimates of progression 
free survival and overall survival of KMT2D (A, B), and TP53 (C, D) mutated versus wild type 
patients. Cases harboring mutations (mut) in these genes are represented by the yellow line. Cases wild 
type (wt) for these genes are represented by the blue line. The Log-rank statistics p values are indicated 
adjacent curves. 
 
Figure 3. Prognostic impact of TP53 deletion. Kaplan-Meier estimates of progression free survival 
(A) and overall survival (B) of TP53 deleted versus wild type patients. Cases with TP53 deletion are 
represented by the yellow line. Cases without TP53 deletion are represented by the blue line. The Log-
rank statistics p values are indicated adjacent curves. 
 
Figure 4. Prognostic impact of combined KMT2D mutations and TP53 disruption. Kaplan-Meier 
estimates of (A) progression free survival and (B) overall survival of patients harboring KMT2D 
mutations and/or TP53 disruption (mutations and/or deletions). Cases harboring at least one of these 3 
genetic lesions are represented by the yellow line. Cases without these genes are represented by the 
blue line. The Log-rank statistics p values are indicated adjacent curves.  
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Figure 5. The “MIPI-g” model. Kaplan-Meier estimates of (A) progression free survival and (B) 
overall survival of patients harboring KMT2D mutations and/or TP53 disruption (mutations and/or 
deletions) integrated into the MIPI-c. Low MIPI-g risk cases are represented by the blue line, 
intermediate MIPI-g cases by the yellow line and high MIPI-g cases by the red line. The Log-rank 
statistics p values are indicated adjacent curves.  
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SUPPLEMENTARY METHODS 
 
Patients series 
The FIL-MCL0208 (NCT02354313) is a phase III, multicenter, open-label, randomized, 
controlled study, designed to determine the efficacy of lenalidomide as maintenance versus 
observation in young (18-65 years old), fit, advanced stage (Ann arbor II-IV) MCL patients who 
achieved complete or partial remission after first line intensified and high-dose chemotherapy plus 
rituximab followed by ASCT. Briefly, patients received 3 R-CHOP-21, followed by R-high-dose 
cyclophosphamide (4g/m2), 2 cycles of R-high-dose Ara-C (2g/m2 q12x3 d) and ASCT conditioned 
by using the BEAM or FEAM regimen. From May 2010 to August 2015, a total of 300 patients were 
enrolled in the study. Cases of non-nodal MCL were excluded.1 All patients required to have a biopsy 
proving MCL, including evidence of cyclin D1 overexpression or t(11;14)(q13;q32) translocation. 
MCL diagnosis was confirmed by centralized pathological revision according to WHO criteria.1 The 
clinical trial, as well as the ancillary mutational study, were approved by the Ethical Committees of 
all the enrolling Centers. All patients provided written informed consent for the use of their biological 
samples for research purposes, in accordance with Institutional Review Boards requirements and the 
Helsinki's declaration. Clinical results of the fist interim analysis of the trial were already presented.2 
Final, unblinded results are not available at the moment and have not been yet presented anywhere. 
 
Biological samples 
Bone marrow (BM) and peripheral blood (PB) samples were collected, as per protocol, at 
baseline and at several time-points during follow-up, corresponding to the pre-planned time-points 
for minimal residual disease (MRD) analysis. To identify and quantify the rate of tumor invasion, 
flow cytometry (FC) was performed both on BM and PB with the following antibodies: anti-CD19 
APC, anti-CD23 PE, anti-CD5 FITC, and anti-CD20. Tumor cells were sorted from the baseline BM 
samples by immunomagnetic beads (CD19 MicroBeads,human-Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) and stocked as dry pellets. 
Tumor DNA was extracted according to DNAzol protocol (Life Technologies). Germline DNA was 
obtained from PB mononuclear cells collected under treatment and proven to be tumor free by MRD 
analysis. 
 
Next generation sequencing 
A targeted resequencing panel (target region: 37’821 bp) (Table S1) including the coding 
exons and splice sites of 7 genes (ATM, TP53, CCND1, WHSC1, KMT2D, NOTCH1 exon 34, BIRC3) 
that are recurrently mutated in ≥ 5% of MCL tumors was specifically designed.3-5 We also included 
in the panel TRAF2 6 and CXCR4.7 The gene panel was analyzed in tumor DNA from baseline BM 
CD19+ purified MCL cells (186 cases) and, for comparative purposes to filter out polymorphisms, in 
the paired normal genomic DNA (105 cases). NGS libraries preparation was performed using TruSeq 
Custom Amplicon sequencing assay according to manufacturer’s protocol (Illumina, Inc., San Diego, 
CA). Multiplexed libraries (n=48 per run) were sequenced using 300-bp paired-end runs on an 
Illumina MiSeq sequencer, (median depth of coverage 2356x). To avoid the loss of NOTCH1 ex 34 
c.7544_7545delCT mutation, that is included in a region poorly covered by the target design, all MCL 
cases were also analyzed by amplification refractory mutation system (ARMS) polymerase chain 
reaction (PCR).  
 
Bioinformatic analysis  
FASTQ sequencing reads were locally aligned to the hg19 version of the human genome 
assembly using the BWA v.0.6.2 software with the default setting, and sorted, indexed and assembled 
into a mpileup file using SAMtools v.1. The aligned read families were processed with mpileup. A 
cut-off of 10% of variant allele frequency (VAF) was set for variant calling. Among cases provided 
with both tumor and paired normal gDNA, single nucleotide variations and indels were called using 
the somatic function of VarScan2. The variants called by VarScan2 were annotated by using the 
SeattleSeq Annotation 138 tool by using the default setting. Variants annotated as SNPs according to 
dbSNP 138 (with the exception of TP53 variants that were manually curated and scored as SNPs 
according to the IARC TP53 database), intronic variants mapping >2 bp before the start or after the 
end of coding exons, and synonymous variants were then filtered out. The following strict post-
processing filters were then applied to the remaining variants to further improve variant call 
confidence. Accordingly, variants represented in >10 reads of the paired germline and/or variants 
with a somatic p value from VarScan2 >3.305e-7 [multiple comparisons corrected p threshold=3.305e-
7, corresponding to alpha of 0.05/(37’821 x 4 alleles per position)] were no further considered. Variant 
allele frequencies for the resulting candidate mutations and the background error rate were visualized 
using IGV. Among patients lacking the paired normal gDNA, single nucleotide variations and indels 
were called in tumor gDNA with the cns function of VarScan2. The variants called by VarScan2 were 
annotated by using the SeattleSeq Annotation 138 tool by using the default setting. Variants annotated 
as SNPs according to dbSNP 138 (with the exception of TP53 variants that were manually curated 
and scored as SNPs according to the IARC TP53 database), intronic variants mapping >2 bp before 
the start or after the end of coding exons, and synonymous variants were then filtered out. Only 
protein truncating variants (i.e. indels, stop codons and splice site mutations), as well as missense 
variants not included in the dbSNP 138 and annotated as somatic in the COSMIC v78 database, were 
retained. 
 
Copy number variation analysis  
DNA profiling was performed on DNA samples derived from baseline BM CD19+ purified 
tumor cells using the HumanOmni2.5 arrays (Illumina, San Diego, CA, USA). Copy number status 
of the genes included in the targeted resequencing panel (KMT2D and TP53) was assessed after 
genomic profiles segmentation with the Fast First-derivative Segmentation Algorithm, as previously 
described.8,9 
Minimal residual disease analysis  
For MRD purposes, MCL diagnostic BM and PB samples were investigated for IGH gene 
rearrangements and BCL1/IGH MTC by qualitative PCR. Briefly, IGH were screened using forward 
consensus primers annealing the IGH-V-regions and a reverse primer complementary to the JH 
region. BCL1/IGH MTC translocation was investigated by nested-PCR approach, as described.10-12 
After direct sequencing, FASTA files alignment was performed by IMGT/V-QUEST 
(http://imgt.org) and BlastN tool (NCBI, https://blast.ncbi.nlm.nih.gov/Blast.cgi), in order to define 
rearranged loci nomenclature, chromosomic breakpoints, and to assess patient specific nucleotide 
insertions (N insertions), then used to design allele specific oligonucleotides primers for nested-PCR 
MRD monitoring. Therefore, both BM and PB samples were analyzed for MRD at specific time 
points during and after treatment. 
 
Statistical analysis 
The primary outcome of the clinical study was progression-free survival (PFS). PFS was 
calculated from the date of enrolment into the clinical study to the date of disease progression (event), 
death from any causes (event), or last follow up (censoring).13 Secondary outcomes included overall 
survival (OS), measured from the date of enrolment into the clinical study to the date of death from 
any causes (event), or last follow up (censoring). Time-to-event outcomes (PFS and OS) were 
estimated using the Kaplan-Meier method and compared between groups using the Log-rank test. 
The adjusted effects of mutations and exposure variables (MIPI-c and blastoid variant) on PFS and 
OS were estimated by Cox regression. To compare clinical baseline features between patients 
enrolled in the molecular study and patients not included in the analysis, we used Mann-Whitney test 
for continuous variables and Pearson’s chi-squared test for categorical variables. A Cox model for 
PFS was estimated including MIPI-c and clinically impacting genetic alterations, and an additive 
score was computed according to the proportion between each predictor coefficient and the lowest 
one. The Cox model was internally validated using 1000 bootstrap samples and the C-statistic correct 
for optimism was also provided. Patients were then grouped in classes of risk according to their total 
score using the nonparametric tree modelling technique of classification and regression tree (CART) 
analysis. Statistical analyses were performed using Stata 13.0 and R 3.4.1. The outcome data for the 
present analysis were updated as of December, 2017 the randomization arms being still blinded. 
 
  
SUPPLEMENTARY FIGURE LEGENDS 
Figure S1. Survival analysis for patients enrolled in the MCL0208 clinical trial included and 
not included in the present molecular study.  Kaplan-Meier estimates of progression free survival 
(A) and overall survival (B) of patients with available DNA included in the present molecular study 
(in blue) and of patients without available DNA not included in the present molecular study (in 
yellow). The Log-rank statistics p values are indicated adjacent curves. 
 
Figure S2. Disposition of identified gene mutations across the protein. Mutations identified in the 
studied cohort are plotted above the protein divided into the main domains. Missense mutations are 
plotted in green, stop codon mutations in red, splicing mutations in black, frameshift mutations in 
red, in-frame mutations in yellow.  
 
Figure S3. Prognostic impact of TP53 mutation and TP53 deletion. Kaplan-Meier estimates of 
progression free survival (A) and overall survival (B) of TP53 mutated patients, TP53 deleted 
patients, TP53 mutated and deleted patients, versus wild type patients. Cases with TP53 mutation are 
represented by the yellow line, cases with TP53 deletion are represented by the red line, cases with 
TP53 mutation and deletion are represented by the black line, cases without TP53 mutation and 
deletion are represented by the blue line. The Log-rank statistics p values are indicated adjacent 
curves. 
 
Figure S4. Prognostic impact of NOTCH1 mutation and ATM mutation. Kaplan-Meier estimates 
of (A) progression free survival and (B) overall survival of patients harboring NOTCH1 mutation and 
Kaplan-Meier estimates of (C) progression free survival and (D) overall survival of patients harboring 
ATM  mutation. Cases harboring NOTCH1 or ATM mutation are represented by the yellow line. Wild 
type cases are represented by the blue line. The Log-rank statistics p values are indicated adjacent 
curves.  
 
Figure S5. Prognostic impact of WHSC1 mutation and CCND1 mutation. Kaplan-Meier 
estimates of (A) progression free survival and (B) overall survival of patients harboring WHSC1 
mutations and Kaplan-Meier estimates of (C) progression free survival and (D) overall survival of 
patients harboring CCND1 mutation. Cases harboring WHSC1 or CCND1 mutation are represented 
by the yellow line. Wild type cases are represented by the blue line. The Log-rank statistics p values 
are indicated adjacent curves. 
 
 
Figure S6. Prognostic impact of  BIRC3 mutation and TRAF2 mutation. Kaplan-Meier estimates 
of (A) progression free survival and (B) overall survival of patients harboring BIRC3 mutation and 
Kaplan-Meier estimates of (C) progression free survival and (D) overall survival of patients harboring 
TRAF2 mutation. Cases harboring BIRC3 or TRAF2 mutation are represented by the yellow line. 
Wild type cases are represented by the blue line. The Log-rank statistics p values are indicated 
adjacent curves. 
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